Furthermore, by decreasing the short isoform of FLIP (FLICE-like inhibitory protein) and Bcl-2, myricetin (150 μM) makes malignant GBM cells more vulnerable to TRAIL-mediated apoptosis [260]. The gene discussed is BCL2; the disease is glioblastoma.